Abstract: The invention includes lipid nanoparticles (LNP) capable of eliciting a modulated immune response against an antigen in a subject. The LNPs comprise: (a) at least one first nucleoside-modified ribonucleic acid (RNA) encoding an antigen; (b) at least one second nucleoside-modified RNA encoding a cytokine or immune receptor (such as but not limited to a cytokine receptor); and (c) at least one ionizable lipid. The invention also includes pharmaceutical compositions comprising the LNP of the invention, as well as a method of eliciting a modulated immune response against an antigen in a subject, the method comprising administering an effective amount of a pharmaceutical compositions comprising the LNP of the invention.

Abstract: The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.

Abstract: The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.

Abstract: The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.

Abstract: Compositions and methods relating to WSX-1 and p28 (IL-30) are provided. In particular, methods of treating inflammatory conditions in mammalian subjects using various WSX-1, p28, EBI3, and gp130 polypeptides and complexes or moieties that bind to or modulate activity of such complexes are described. Isolated or recombinant complexes including soluble WSX-1 or gp130 polypeptides, isolated or recombinant WSX-1 fusion proteins, and isolated or recombinant p28 fusion proteins are also described.

Abstract: The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.

Abstract: Provided are methods increasing, or, alternatively, decreasing IL-6 and/or gp130-mediated signaling in mammalian subjects using p28. Methods of preventing and/or treating autoimmune disorders, cancer, transplant rejection, and other IL-6-associated diseases, as well as methods of enhancing an IL-6-mediated immune response, are also described.